Takeda Says U.S. FDA To Delay Approval Of Replacement Diabetes Drug
This article was originally published in PharmAsia News
Takeda Pharmaceutical said U.S. FDA has delayed review of alogliptin until the Japanese drug maker can supply more data about the diabetes drug. The delay was seen as a blow to Takeda, which faces a 2011 patent expiration on its best-seller Actos (pioglitazone) for treating Type 2 diabetes. Takeda submitted data about the drug candidate at the end of 2007, but FDA said the information did not meet new standards adopted by the agency last year. (Click here for more
You may also be interested in...
House and Senate Democrats sponsor legislation to authorize FTC enforcement against sales of "consumer goods and services at an unconscionably excessive price during the" COVID-19 pandemic. "It’s outrageous that some companies and individuals are taking advantage of consumers by price-gouging," says Energy and Commerce Committee Chairman Frank Pallone.
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”